Participants who started directly at 4 mg experienced nearly twice the rate of gastrointestinal symptoms compared to those who titrated up from 2 mg
Nicole Snow The Olympia team partners with you and your provider to support your long-term wellness, helping you stay consistent with your age management plan
PMID 25751285
Disclosures The LEADER, SUSTAIN-6, REWIND, PIONEER 6, SELECT, SOUL, STEP-HFpEF (with and without diabetes), and FLOW trials were sponsored by Novo Nordisk
These figures describe research arms, not a universal retatrutide dosing schedule
The most commonly reported side effects are gastrointestinal, including nausea, vomiting, diarrhoea, and constipation, particularly during dose escalation